Page last updated: 2024-11-08

methenolone acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methenolone acetate: RN given refers to (5alpha,17beta)-isomer; structure in Negwer, 5th ed, #5015 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID252372
CHEMBL ID2106880
CHEBI ID31828
SCHEMBL ID1181725
MeSH IDM0103240

Synonyms (61)

Synonym
androst-1-en-3-one, 17-(acetyloxy)-1-methyl-, (5alpha,17beta)-
einecs 207-097-0
testosterone, 1-dehydro-4,5alpha-dihydro-1-methyl-, acetate
methenolone 17-acetate
17beta-hydroxy-1-methyl-5alpha-androst-1-en-3-one acetate
methenolone acetate [usan]
nsc 74226
17-beta-hydroxy-1-methyl-5-alpha-androst-1-en-3-one acetate
5alpha-androst-1-en-3-one, 17beta-hydroxy-1-methyl-, acetate
5-alpha-androst-1-en-3-one, 17-beta-hydroxy-1-methyl-, acetate
androst-1-en-3-one, 17-(acetyloxy)-1-methyl-, (5-alpha,17-beta)-
sq 16496
primobolone
nibal
methenolone acetate
primonabol
testosterone,5.alpha.-dihydro-1-methyl-, acetate
sh 567
metenolone acetate
nsc-74226
nsc74226
sh 567a
premobolan
5.alpha.-androst-1-en-3-one, acetate
primobolan
17.beta.-hydroxy-1-methyl-5.alpha.-androst-1-en-3-one acetate
434-05-9
C15804
D01375
metenolone acetate (jp17)
methenolone acetate (usan)
primobolan (tn)
[(5s,8r,9s,10s,13s,14s,17s)-1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
A826271
oral primobolan
so 16496
CHEMBL2106880
sq-16496
sh-567
w75590vpkq ,
unii-w75590vpkq
AKOS015895244
metenolone acetate [mart.]
metenolone acetate [jan]
methenolone 17-acetate [mi]
androst-1-en-3-one, 17-(acetyloxy)-1-methyl-, (5.alpha.,17.beta.)-
metenolone acetate [who-dd]
SCHEMBL1181725
CS-4517
W-106232
androst-1-en-3-one, 17-(acetyloxy)-1-methyl-, (5a,17b)-
methenolone (acetate)
HY-A0094B
CHEBI:31828
NCGC00484057-01
methenolone acetat
Q27292427
DTXSID40963004
AS-57218
methenolone acetate 100 microg/ml in methanol
metenolone acetate, 1mg/ml in isopropanol

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Thus, the androgen therapy in combination with hematopoietic growth factors such as G-CSF and/or Epo may be effective in patients with RA."( Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia.
Harada, M; Katayama, Y; Kojima, K; Omoto, E, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" No methenolone or characteristic major metabolite was detected in samples from subjects who ate meat from the orally dosed chickens."( Effect on sports drug tests of ingesting meat from steroid (methenolone)-treated livestock.
Cowan, DA; Kicman, AT; Myhre, L; Nilsson, S; Oftebro, H; Tomten, S, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroid ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (33.33)18.7374
1990's11 (36.67)18.2507
2000's3 (10.00)29.6817
2010's4 (13.33)24.3611
2020's2 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.90 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index68.22 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (45.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.23%)5.53%
Reviews1 (3.23%)6.00%
Case Studies8 (25.81%)4.05%
Observational0 (0.00%)0.25%
Other21 (67.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]